How do Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) work in controlling Abnormal Uterine Bleeding (AUB)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mechanism of Action: NSAIDs in Controlling Abnormal Uterine Bleeding

NSAIDs reduce abnormal uterine bleeding by 25-50% through inhibition of prostaglandin synthesis in the endometrium, which decreases both menstrual blood flow and associated dysmenorrhea. 1, 2, 3

How NSAIDs Work at the Molecular Level

NSAIDs control AUB through a specific endometrial mechanism:

  • Prostaglandin inhibition: NSAIDs block cyclooxygenase enzymes, reducing prostaglandin E2 and F2-alpha production in the endometrium, which are elevated in women with heavy menstrual bleeding 4, 3

  • Vasoconstriction effect: Decreased prostaglandin levels lead to increased endometrial vasoconstriction and reduced blood flow during menstruation 3

  • Hemostatic improvement: The altered prostaglandin balance favors platelet aggregation and local hemostasis within the endometrial vasculature 4

Clinical Efficacy Data

The reduction in menstrual blood loss is clinically significant but modest:

  • Expected reduction: 30-50% decrease in menstrual blood volume compared to placebo 5, 4
  • Pain control: Simultaneous improvement in dysmenorrhea through the same prostaglandin-blocking mechanism 2, 3
  • Comparative effectiveness: NSAIDs are less effective than tranexamic acid (40-60% reduction), levonorgestrel IUD (65-85% reduction), or combined oral contraceptives (40-50% reduction) 5, 4, 3

Position in Treatment Algorithm

NSAIDs are recommended as first-line therapy for AUB, particularly when hormonal contraception is contraindicated or the patient desires immediate fertility. 1, 5

  • Optimal candidates: Women with ovulatory dysfunctional uterine bleeding who need non-hormonal management 5, 6
  • Treatment duration: Short-term use for 5-7 days during menstruation is typically sufficient 2
  • Preferred agents: Mefenamic acid, flufenamic acid, and indomethacin have demonstrated efficacy, with naproxen and ibuprofen preferred for patients with cardiovascular risk factors 2

Critical Safety Considerations and Contraindications

NSAIDs should generally be avoided in women with spontaneous coronary artery dissection (SCAD) or significant cardiovascular disease due to their association with myocardial infarction and thrombosis. 7

  • Cardiovascular caution: Use with extreme caution in patients with known cardiovascular disease, as NSAIDs carry thrombotic risk 7, 2
  • Gastrointestinal risk: Avoid in patients with peptic ulcer disease history, advanced age (>60 years), or concurrent corticosteroid therapy 2
  • Antiplatelet interaction: In women on dual antiplatelet therapy (such as post-SCAD patients), NSAIDs are contraindicated as they compound bleeding risk while paradoxically increasing thrombotic risk 7

When NSAIDs Are Insufficient

If NSAIDs fail to adequately control bleeding after 3 menstrual cycles:

  • Next step: Progress to tranexamic acid (non-hormonal alternative with superior efficacy) or levonorgestrel IUD if contraception is acceptable 1, 5
  • Combination therapy: NSAIDs may be combined with other agents, though this approach requires careful monitoring 6
  • Surgical consideration: For refractory cases in women not desiring future fertility, endometrial ablation techniques provide superior long-term efficacy compared to continued medical management 5

References

Guideline

Medical Management of Uterine Fibroids

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

NSAIDs as First-Line Treatment for Dysmenorrhea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacological therapy for abnormal uterine bleeding.

Menopause (New York, N.Y.), 2011

Research

Therapies for the treatment of abnormal uterine bleeding.

Current women's health reports, 2001

Research

Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause.

European journal of obstetrics, gynecology, and reproductive biology, 2010

Research

Management of abnormal uterine bleeding.

American journal of obstetrics and gynecology, 1996

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.